Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these compounds increase insulin secretion and suppress gluca

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing differences in the